Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Mucci, Tania MD,; Davis-Lorton, Mark MD
Abstract: Fidaxomicin is a recently Food and Drug Administration–approved oral medication for the treatment of Clostridium difficile infection. This medication is typically reserved for patients who have failed therapy with oral metronidazole. Here we present a case of a 79-year-old man with recurrent C. difficile infection who developed pitting lower extremity edema and a confluent, purpuric drug eruption 3 days into treatment with fidaxomicin. The rash improved completely with cessation of the medication. To our knowledge, this is the first report of a purpuric drug eruption secondary to fidaxomicin.
© 2014 Wolters Kluwer Health, Inc. All rights reserved.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at Infectious Diseases in Clinical Practice.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Save my selection
adverse drug reaction, C. difficile, drug rash, purpura, delayed hypersensitivity reaction, allergy, fidaxomicin, difficid
Search for Similar Articles
You may search for similar articles that contain these same keywords or you may
modify the keyword list to augment your search.